Obeticholic acid (OCA) is emerging as a vital player in the treatment landscape of chronic liver disorders, particularly primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). A semi-synthetic derivative of chenodeoxycholic acid, OCA functions as a potent and highly selective agonist of the farnesoid X receptor (FXR) — a nuclear receptor that governs critical metabolic […]